Search

Your search keyword '"Cibele Masotti"' showing total 2 results
Start Over Author "Cibele Masotti" Publisher public library of science (plos)
2 results on '"Cibele Masotti"'

1. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

Author

Fabricio de Carvalho, Erico T Costa, Anamaria A Camargo, Juliana C Gregorio, Cibele Masotti, Valeria C C Andrade, Bryan E Strauss, Otavia L Caballero, Djordje Atanackovic, and Gisele W B Colleoni

Subjects
Medicine, Science
Abstract

The MAGE-C1/CT7 encodes a cancer/testis antigen (CTA), is located on the chromosomal region Xq26-27 and is highly polymorphic in humans. MAGE-C1/CT7 is frequently expressed in multiple myeloma (MM) that may be a potential target for immunotherapy in this still incurable disease. MAGEC1/CT7 expression is restricted to malignant plasma cells and it has been suggested that MAGE-C1/CT7 might play a pathogenic role in MM; however, the exact function this protein in the pathophysiology of MM is not yet understood. Our objectives were (1) to clarify the role of MAGE-C1/CT7 in the control of cellular proliferation and cell cycle in myeloma and (2) to evaluate the impact of silencing MAGE-C1/CT7 on myeloma cells treated with bortezomib. Myeloma cell line SKO-007 was transduced for stable expression of shRNA-MAGE-C1/CT7. Downregulation of MAGE-C1/CT7 was confirmed by real time quantitative PCR and western blot. Functional assays included cell proliferation, cell invasion, cell cycle analysis and apoptosis. Western blot showed a 70-80% decrease in MAGE-C1/CT7 protein expression in inhibited cells (shRNA-MAGE-C1/CT7) when compared with controls. Functional assays did not indicate a difference in cell proliferation and DNA synthesis when inhibited cells were compared with controls. However, we found a decreased percentage of cells in the G2/M phase of the cell cycle among inhibited cells, but not in the controls (p

Published
2011
Full Text
View/download PDF

2. Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines

Author

Bryan E. Strauss, Djordje Atanackovic, Erico T. Costa, Gisele W. B. Colleoni, Anamaria A. Camargo, Otavia L. Caballero, Valeria C.C. Andrade, Juliana C. Gregorio, Cibele Masotti, and Fabricio de Carvalho

Subjects
B Cells, Apoptosis, Hematologic Cancers and Related Disorders, Bortezomib, Molecular cell biology, RNA interference, RNA, Small Interfering, Multiple myeloma, Multidisciplinary, Cell Death, Chromosome Biology, Hematology, Cell cycle, Flow Cytometry, Boronic Acids, Neoplasm Proteins, Nucleic acids, Gene Expression Regulation, Neoplastic, Eukaryotic Cells, Pyrazines, Medicine, Immunotherapy, Cellular Types, Multiple Myeloma, Proteasome Inhibitors, Cell Division, Research Article, medicine.drug, G2 Phase, endocrine system, Immune Cells, Science, Immunology, Mitosis, Bone Marrow Cells, Antineoplastic Agents, Biology, Antigen, Antigens, Neoplasm, Cell Line, Tumor, Genetics, Cancer Genetics, medicine, Humans, Neoplasm Invasiveness, Protease Inhibitors, Myelomas and Lymphoproliferative Diseases, Gene Silencing, neoplasms, Cell Proliferation, Cell growth, Immunity, medicine.disease, Molecular biology, Cell culture, Humoral Immunity, Proteasome inhibitor, RNA, Gene expression, Gene Function, Cytometry
Abstract

The MAGE-C1/CT7 encodes a cancer/testis antigen (CTA), is located on the chromosomal region Xq26–27 and is highly polymorphic in humans. MAGE-C1/CT7 is frequently expressed in multiple myeloma (MM) that may be a potential target for immunotherapy in this still incurable disease. MAGEC1/CT7 expression is restricted to malignant plasma cells and it has been suggested that MAGE-C1/CT7 might play a pathogenic role in MM; however, the exact function this protein in the pathophysiology of MM is not yet understood. Our objectives were (1) to clarify the role of MAGE-C1/CT7 in the control of cellular proliferation and cell cycle in myeloma and (2) to evaluate the impact of silencing MAGE-C1/CT7 on myeloma cells treated with bortezomib. Myeloma cell line SKO-007 was transduced for stable expression of shRNA-MAGE-C1/CT7. Downregulation of MAGE-C1/CT7 was confirmed by real time quantitative PCR and western blot. Functional assays included cell proliferation, cell invasion, cell cycle analysis and apoptosis. Western blot showed a 70–80% decrease in MAGE-C1/CT7 protein expression in inhibited cells (shRNA-MAGE-C1/CT7) when compared with controls. Functional assays did not indicate a difference in cell proliferation and DNA synthesis when inhibited cells were compared with controls. However, we found a decreased percentage of cells in the G2/M phase of the cell cycle among inhibited cells, but not in the controls (p

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results